Institut Gustave-Roussy

Research / Science organisation


Location: Villejuif, France (FR) FR

ISNI: 0000000122849388

ROR: https://ror.org/0321g0743

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008 (2021) Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, Mohr P, et al. Conference contribution Radiomics for selection of patients treated with immuno-radiotherapy: pooled analysis from 6 studies (2020) Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Milic M, Carre A, et al. Conference contribution Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Conference contribution Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells (2020) Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, Milic M, et al. Journal article EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation (2020) Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, et al. Conference contribution Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI). (2020) Rogiers A, Tondini C, Grimes JM, Trager MH, Nahm S, Zubiri L, Papneja N, et al. Conference contribution Development of an immunological prognostic Signature in metastatic Patients who were treated with Immune Checkpoint Inhibitors as part of the ST-ICI Study (2020) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes (2020) Kroeze LI, de Voer RM, Kamping EJ, von Rhein D, Jansen EA, Hermsen MJ, Barberis MC, et al. Journal article Solving the preoperative breast MRI conundrum: design and protocol of the MIPA study (2020) Sardanelli F, Trimboli RM, Houssami N, Gilbert FJ, Helbich TH, Alvarez Benito M, Balleyguier C, et al. Journal article
1 ... 3 4 5 6 7 8